Cryo-electron microscopy (Cryo-EM) has advanced the way scientists visualize biomolecules in their native states, with resolutions as high as 1.5 Å. This ability to unlock high-resolution structures without requiring crystallization has made cryo-EM an important tool for understanding complex proteins and macromolecular aggregates. By preserving biomolecules in a near-native state through vitrification, cryo-EM captures detailed density maps that prompt the construction of atomic models. This technology holds immense promise for public health by advancing our understanding of diseases like Parkinson’s, which affects millions worldwide. By informing the structural basis of disease mechanisms, cryo-EM is driving innovations in diagnostics and targeted therapies (Bhella, 2019).
The procedure for cryo-EM is designed to preserve and visualize macromolecules at near-atomic resolution. The process begins by purifying the target protein or macromolecular complex and preparing it in a stable, native-like solution. A small volume of the solution with the sample is then applied to a grid coated with a thin carbon film. After blotting to remove excess liquid, the grid is almost instantly frozen in liquid ethane, which is a critical step that vitrifies the sample and preserves its structure in a near-native state. Once vitrification is done, the grid is transferred to an electron microscope, where an electron beam captures thousands of two-dimensional projection images of the sample from various angles. These images are collected at cryogenic temperatures to prevent damage and maintain resolution, and then they are computationally processed to correct for motion, align particles, and filter noise. By collecting data, a three-dimensional density map of the macromolecule is reconstructed that reveals its shape and arrangement. Finally, atomic models are constructed from the density map, enabling researchers to analyze the biomolecule’s structure, function, and interactions. This integration of advanced imaging techniques with computational analysis demonstrates why cryo-EM is a transformative tool in structural biology and its implications for disease research and drug discovery (Knot, 2023).
Several advantages have demonstrated why cryo-EM is a preferred tool in structural biology. First, cryo-EM does not require crystallization, a time-consuming and often not feasible step in X-ray crystallography, which makes cryo-EM ideal for studying dynamic and flexible molecules that are difficult to crystallize (Kühlbrandt, 2014). Second, this technique is particularly well-suited for large macromolecular complexes, such as ribosomes, viruses, and membrane proteins, as those cannot be properly studied using techniques like NMR spectroscopy due to size limitations (Bai et al., 2015). Additionally, cryo-EM preserves samples close to their native states by freezing them in vitreous ice, ensuring that biomolecules retain their natural conformations during imaging (Kühlbrandt, 2014). Another advantage is cryo-EM’s ability to capture multiple conformations of biomolecules due to the sudden freezing, which enables researchers to study dynamic processes such as enzyme activity and ligand binding (Bai et al., 2015). Finally, cryo-EM’s broad applicability makes it very useful for investigating complex samples like protein aggregates in neurodegenerative diseases and multi-component molecular assemblies (Bai et al., 2015). These strengths highlight cryo-EM’s transformative impact on structural biology and its growing role in therapeutic development.
Parkinson’s Disease is a progressive neurodegenerative disorder that primarily affects movement, balance, and coordination. This condition results from the degeneration of neurons in the substantia nigra, a region of the brain responsible for producing dopamine. The loss of these neurons leads to the characteristic motor symptoms of Parkinson’s Disease, including tremors, rigidity, and bradykinesia (U.S. Department, 2024). A notable component of the disease is the formation of Lewy bodies, which are unusual aggregates of the protein alpha-synuclein. These aggregates disrupt cellular processes, contribute to neurotoxicity, and ultimately lead to neuronal death. Understanding the structure and aggregation of alpha-synuclein is beneficial for determining the mechanisms underlying Parkinson’s Disease and for developing targeted treatments.
So far, cryo-EM has mainly provided structural insights into alpha-synuclein fibrils, a key protein involved in Parkinson’s Disease. One of the most significant findings is the identification of structural polymorphisms in these fibrils, which means that alpha-synuclein can aggregate into multiple structural forms. These polymorphisms are particularly important because they may correspond to distinct disease subtypes or variations in progression rates (Guerrero-Ferreira et al., 2018). This structural diversity helps explain why Parkinson’s Disease manifests differently among patients, with certain polymorphic forms being more toxic or spreading more rapidly between neurons. These insights can inform personalized treatment strategies, offering hope for patients with diverse disease trajectories. By targeting specific aggregation pathways, cryo-EM is paving the way for therapies that reduce disease severity and enhance patient outcomes (Guerrero-Ferreira et al., 2018).
Figure 1: Structural polymorphisms of alpha-synuclein fibrils. (A) Protein sequence of alpha-synuclein highlighting mutations (red). (B, C) Low- and high-magnification cryo-EM images of fibrils. (D) Cross-sectional view showing beta-sheet stacking. (E) 3D reconstruction of fibrils with protofilaments (blue and orange) and key amino acids labeled. Panels adapted from Guerrero-Ferreira et al., 2018 (eLife, https://doi.org/10.7554/eLife.36402).
The visual above (Figure 1) further illustrates the structural complexity of alpha-synuclein fibrils captured by cryo-EM. Panel A lists the amino acid sequence of alpha-synuclein fibrils and Highlights mutations such as A53P, E46K, and H50Q in red to emphasize their role in altering fibril formation and disease progression. Low- and high-magnification in panels B and C show electron microscopy images of filament-like aggregates and their periodic structure, and the cross-sectional views in panel D reveals the stacked beta-sheet architecture of amyloid fibrils. The 3D cryo-EM reconstruction in panel E illustrates atomic-level detail by showing how protofilaments twist together and critical amino acid interactions. All together these visuals depict how cryo-EM complements other visualization techniques and contributes to a comprehensive understanding of alpha-synuclein’s structural variations. (Guerrero-Ferreira et al., 2018).
Beyond alpha-synuclein, cryo-EM also has broader applications in Parkinson’s Disease research. An important finding in this field relates to Leucine-rich repeat kinase 2 (LRRK2), a key genetic risk factor for Parkinson’s Disease. Cryo-EM has provided detailed structural insights into LRRK2 which has inspired the development of targeted inhibitors to modulate its activity and reduce neuronal damage (Ahmadi Rastegar & Dzamko, 2020). Mutations in LRRK2, such as R1441C and G2019S, are strongly linked to Parkinson’s Disease and often result in hyperactivation of kinase activity that disrupts cellular homeostasis.
Additionally, cryo-EM has been applied to study tau fibrils, which often also occur in diseases similar to Parkinson’s. Comparing the structures of tau and alpha-synuclein aggregates reveals both shared and unique aggregation mechanisms which helps in understanding overlapping neurodegenerative pathologies. Furthermore, cryo-EM is useful for observing the interactions between alpha-synuclein and cellular membranes and helps researchers understand how these interactions contribute to neurotoxicity. It also provides insights into synaptic proteins affected by Parkinson’s Disease by providing a more comprehensive molecular view of the disease (Ahmadi Rastegar & Dzamko, 2020).
These applications demonstrate cryo-EM’s versatility in Parkinson’s research, spanning from structural biology to therapeutic advancements. By enabling scientists to visualize complex protein structures and interactions, cryo-EM continues to play a pivotal role in advancing our understanding of Parkinson’s Disease and developing potential treatments.
While cryo-EM is and might continue to be transformative in Parkinson’s research, there are also several limitations with this technique. Sample preparation poses challenges, as proteins like alpha-synuclein fibrils are prone to aggregation, which results in heterogeneous samples that can complicate visualization or structural analysis. Moreover, structural heterogeneity in macromolecular complexes like alpha-synuclein fibrils can often result in suboptimal resolutions that lose critical details of more mobile regions. It is also difficult to reach optimal vitrification and consistent ice thickness during the grid preparation step of the procedure (Renaud et al., 2018). Additionally, cryo-EM struggles with resolving smaller proteins under 50 kDa, which limits its application to certain targets. Computational demands are another limitation, as cryo-EM generates large datasets that require advanced algorithms and processing power. While cryo-EM faces challenges in sample preparation and computational demands, ongoing advancements aim to overcome these barriers. Addressing these issues is critical for extending the technique’s utility in public health, particularly for studying diseases that place a significant burden on healthcare systems.
To recapitulate, cryo-electron microscopy has enhanced structural biology studies by offering detailed insights into biomolecular architecture. Its application in Parkinson’s Disease research exemplifies its potential, as it has provided critical understanding of protein aggregation, aided drug development, and uncovered mechanisms of neurodegeneration. Cryo-EM is truly transforming our understanding of neurodegenerative diseases like Parkinson’s, providing essential insights into protein aggregation and therapeutic targets. By enabling precise diagnostics and paving the way for innovative treatments, this technology has the potential to significantly reduce the global burden of such diseases, underscoring its importance in advancing public health.
References
Ahmadi Rastegar, D., & Dzamko, N. (2020). Leucine Rich Repeat Kinase 2 and innate
immunity. Frontiers in Neuroscience, 14, Article 193. https://doi.org/10.3389/fnins.2020.00193
Bai, X., McMullan, G., & Scheres, S. H. W. (2015). How Cryo-EM is revolutionizing structural
biology. Trends in Biochemical Sciences. [Discusses the technical benefits and application of Cryo-EM.]
Bhella, D. (2019). Cryo-electron microscopy: An introduction to the technique, and
considerations when working to establish a national facility. Biophysical Reviews, 11(4),
Guerrero-Ferreira, R., Taylor, N. M. I., Mona, D., Ringler, P., Lauer, M. E., Riek, R., Britschgi,
M., & Stahlberg, H. (2018). Cryo-EM structure of alpha-synuclein fibrils. eLife, 7, e36402. https://doi.org/10.7554/eLife.36402
Kühlbrandt, W. (2014). The Resolution Revolution. Science. [Explains Cryo-EM’s advantages
over crystallography and NMR.]
Renaud, J. P., Chari, A., Ciferri, C., et al. (2018). Cryo-EM in drug discovery: Achievements,
limitations, and prospects. Nature Reviews Drug Discovery, 17(5), 471–492.
U.S. Department of Health and Human Services. (n.d.). Parkinson’s disease. National Institute of
Neurological Disorders and Stroke. Retrieved December 14, 2024, from
Comments